Molecular Partners Ag (MOLN) Consolidated Net Income (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Consolidated Net Income of -$16792.1 for Q1 2026, up 10.0% year-on-year from -$15266.2 in Q1 2025, and up 99.98% on a QoQ basis from -$81.8 million in Q4 2025.
Molecular Partners Ag (MOLN) Consolidated Net Income (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Consolidated Net Income for 7 consecutive years, with -$16792.1 the latest figure, recorded in Q1 2026.
- Quarterly Consolidated Net Income rose 10.0% year-over-year to -$16792.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.9 million (down 31.54% YoY) and the FY2025 annual result came in at -$81.9 million, down 31.55% from the prior year.
- Consolidated Net Income advanced to -$16792.1 in Q1 2026 per MOLN's latest filing, from -$81.8 million in the prior quarter.
- Over the last five years, Consolidated Net Income for MOLN reached as high as $127.7 million in Q4 2022 and fell as low as -$81.8 million in Q4 2025.
- A 5-year average of -$6.5 million and a median of -$16792.1 in 2026 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income jumped 1005.54% — and 2023, when it tumbled 278.7%.
- Year by year, Consolidated Net Income stood at $127.7 million in 2022, then plunged by 156.44% to -$72.1 million in 2023, then grew by 13.69% to -$62.2 million in 2024, then sank by 31.56% to -$81.8 million in 2025, then surged by 99.98% to -$16792.1 in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$16792.1, -$81.8 million, and -$14803.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -16,792.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,792.10 |
| Dec 31, 2025 | -81.84 Mn |
| Sep 30, 2025 | -14,803.30 |
| Jun 30, 2025 | -24,645.31 |
| Mar 31, 2025 | -18,656.89 |
| Dec 31, 2024 | -62.21 Mn |
| Sep 30, 2024 | -18,940.19 |
| Jun 30, 2024 | -16,677.58 |
| Mar 31, 2024 | -12,981.38 |
| Dec 31, 2023 | -72.07 Mn |
| Sep 30, 2023 | -12,957.15 |
| Jun 30, 2023 | -17.78 Mn |
| Mar 31, 2023 | -15,983.58 |
| Dec 31, 2022 | 127.71 Mn |
| Sep 30, 2022 | -13,800.36 |
| Jun 30, 2022 | -4.70 Mn |
| Mar 31, 2022 | 165,800.92 |
| Dec 31, 2021 | -69.13 Mn |
| Sep 30, 2021 | -13,411.64 |
| Jun 30, 2021 | -36.79 Mn |